Envoy Medical, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Brent T. Lucas
- Full Time Employees
- 43
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 4875 White Bear Parkway White Bear Lake MN United States of America 55110
- IPO Date
- Apr 29, 2021
- CIK
- 0001840877
- Website
- envoymedical.com
- Similar Companies
- Business
- Envoy Medical, Inc. is a hearing health company specializing in fully implanted hearing devices and medical technologies across the hearing loss spectrum. Its core products include the Esteem® active middle ear implant, commercially available in the U.S. since 2010, and the investigational fully implanted Acclaim® cochlear implant designed for severe to profound sensorineural hearing loss. Additional product offerings encompass bone conduction devices such as auditory osseointegrated implants. The company focuses on leveraging natural ear anatomy with sensor technology to enhance sound capture, aiming to improve access, usability, compliance, and quality of life for patients. Founded in 1995 and headquartered in White Bear Lake, Minnesota, Envoy Medical operates primarily in the U.S. market with ongoing clinical trials and regulatory advancements. Recent strategic developments include the successful elimination of over $32 million in long-term debt, significantly strengthening the company's balance sheet and shareholder equity. Envoy Medical recently secured FDA approval to expand the pivotal clinical trial for the Acclaim cochlear implant to its second and final stage, enrolling additional participants across multiple U.S. sites. The company has enhanced its global patent portfolio with new patents granted in the U.S., Europe, and Australia, reinforcing its leadership in fully implanted hearing technologies. Furthermore, Envoy Medical raised approximately $4 million through a registered direct offering to fund ongoing operations and development efforts. The company also achieved favorable reimbursement strategies for the Esteem implant and continued to focus on scaling commercialization efforts for its technology. Envoy Medical emphasizes innovation within the hearing healthcare industry, targeting adults with various degrees of hearing loss through advanced, fully implanted solutions. This strategic positioning and financial strengthening support Envoy Medical’s goal to expand its market presence and drive adoption of next-generation hearing devices.
Envoy Medical Surpasses Three-Month Visit Milestone for All 56 Patients in Pivotal Clinical Trial
Envoy Medical Reports Positive 12-Month Data Showing Continued Improvement in Speech Perception in Study of First-of-Its-Kind Fully Implanted Cochlear Implant
Envoy Medical Submits First Module of Modular Premarket Approval Application to the U.S. Food and Drug Administration for Breakthrough-Designated Device
Envoy Medical Terminates At-the-Market (ATM) Equity Facility
Envoy Medical to Present at Investor Conferences on June 25th
Envoy Medical to Present at Planet MicroCap Conference Las Vegas on June 16th-18th
Envoy Medical Announces New Patents Expanding Intellectual Property Portfolio in Fully Implanted Hearing Technology
Envoy Medical Reports Landmark Accomplishments, Advancing Toward FDA Approval of First-of-Its-Kind Fully Implanted Cochlear Implant
Envoy Medical Highlights First Clinical Data Presentations from Pivotal Clinical Study of Fully Implanted Acclaim(R) Cochlear Implant
Envoy Medical Appoints Chas McKhann to Board of Directors
Envoy Medical Announces First Patients Successfully Reaching 12-Month Endpoint in Pivotal Clinical Trial for Fully Implanted Cochlear Implant
Envoy Medical Reports Full Year 2025 Financial Results
Financial Analysis: Competitive Technologies (OTCMKTS:CTTC) vs. Envoy Medical (NASDAQ:COCH)
Envoy Medical Completes Enrollment of Pivotal Clinical Trial Evaluating First-Of-Its-Kind Fully Implanted Cochlear Implant
Envoy Medical Regains Compliance with Nasdaq Listing Requirement
Envoy Medical Secures Three New Patents Strengthening Competitive Position in the Fully Implanted Hearing Space
Analyzing Envoy Medical (NASDAQ:COCH) and TearLab (OTCMKTS:TEAR)
Envoy Medical Provides Business Update Following Transformative Financing and Positive Progress in Clinical Trial
Envoy Medical (NASDAQ:COCH) Major Shareholder Glen Taylor Buys 18,750,000 Shares of Stock
Envoy Medical Nears Completion of Enrollment in Pivotal Clinical Trial of Fully Implanted Acclaim(R) Cochlear Implant